Rotella Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Rotella Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,182	Closed	-$20K	–	392
2015 Q4	$20K	Sell	1,182 -2,020	-63%	-$48.2K	0.02%	390
2015 Q3	$68K	Buy	+3,202	New	+$110K	0.02%	474
2015 Q1	–	Sell	-3,057	Closed	-$185K	–	693
2014 Q4	$185K	Buy	+3,057	New	+$154K	0.16%	154

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Rotella Capital Management's OREX Position: Q1 2016 in Review

Rotella Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 1,182 shares — an estimated $20K sold.

Rotella Capital Management first reported a position in OREX in Q4 2014 and held it in 3 quarters. The position peaked at $185K in Q4 2014. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

Rotella Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Rotella Capital Management sold 1,182 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $20K.
Rotella Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
Rotella Capital Management's Orexigen Therapeutics, Inc. position peaked at $185K in Q4 2014.
104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.